Uromac®, sterile hyaluronic acid solution for vesical irrigation, presented in a 50 millilitre vial with 100mg of hyaluronic acid. The product is sterile and single use. It must not be re-used under any circumstances.

Description of the photograph


Uromac® is a protective preparation for the intimate vesical and urethral mucosa. It is a sterile medical product which represents an evolution in the use of sodium salt from hyaluronic acid, a polysaccharide widely present in the tissues of the human body, where it has diverse and fundamental biological functions, in particular and thanks to its protective and film-forming properties, it permits a more natural and a safer process of cellular regeneration.

Uromac® is well tolerated by the organism, produces no undesirable effects and has no specific contra-indications.

The integrity of the epithelial tissue which constitutes the vesical mucosa is fundamental for ensuring the natural protective and barrier function played by the tissue when faced with aggressions from pathogen agents, micro-organisms and toxic substances.

Uromac®, hyaluronic acid of low molecular weight and very low viscosity, has been developed thanks to these properties to fulfull a contributory protective function in processes of re-epithelialization of the vesical and urethral mucosa.

To follow, you can download the promotional brochure containing all the information you need about Uromac®

Download ZIP (1,160 kb)


Uromac® is a medical product consisting of hyaluronic acid indicated as preserver and protector of the vesical and urethral mucosa capable of favouring the physiological process of repairing lesions of the mucosa.

Uromac® is indicated in radiotherapy both as prophylaxis and contributor to the repair of the vesical mucosa in patients who are subjected to radiation, in urology when the vesical and urethral mucosa have been damaged, in gynaecology for invasive gynaecological examinations and for surgery where said mucosae have been damaged or may be so.


Bibliographic References

  1. Pimentel AA y cols. Efectos del ácido hialurónico sobre el mecanismo de la cicatrización en la anastomosis de la uretra. Bol Col. Mexicano de Urología. 2001 Ene-Mar. 27(1):26-31
  2. Morales A, Emerson L, Nickel JC, Lundie M. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. The Journal of Urology. 1996 Jul; 156:45-48
  3. Takahashi K, Takeuchi J, Takahashi T, Miyauchi S, Horie K, Uchiyama Y. Effects of the sodium hyaluronate on epithelial healing of the vesical mucosa and vesical fibrosis in rabbits with acetic acid induced cistitits. The Journal of Urology. 2001 Aug; 166:710-713
  4. Erickson DR, Sheykhnazari M, Ordile S, Bhavanandan VP. Increased urinari hyaluronic acid and interstitial cystitis. The Journal of Urology. 1998 Oct; 160:1282-1284
  5. Toft BR, Nordling J. Recent developtments of intravesical therapy of painful bladder sindrome/interstitial cistitis: a review. Current Opinion in Urology. 2006; 16:268-272
  6. Cipe FE, Soygür T, Doğu F, Erdoğan O, Bozdoğan G, Ikincioğullari A. Late onset hemorragia cistitis in a hematopoietic item recipient: Treatment with intravesical hyaluronic acid. Pediatr. Transplantation 2010; 14:E79-E82

C/ Azcárraga, 12 A, P-2, 3ºC 33010 Oviedo. Spain.

Legal Notice Design and development by [Q]